"10.1371_journal.pone.0097232","plos one","2014-05-09T00:00:00Z","Kihyuck Kwak; Rosie Jiang; Joshua W Wang; Subhashini Jagu; Reinhard Kirnbauer; Richard B S Roden","Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, United States of America; Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University Vienna (MUW), Vienna, Austria","Conceived and designed the experiments: RBSR KK. Performed the experiments: KK RJ JWW SJ. Analyzed the data: KK RJ JWW SJ RK RBSR. Contributed reagents/materials/analysis tools: RK RBSR. Wrote the paper: KK RK RBSR.","This study was partly funded by Sanofi Pasteur. Subhashini Jagu and Richard Roden are co-inventors on L2 patents (20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies and 20100297144 MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION), licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc., and Acambis, Inc., and have received research funding from Shantha Biotechnics Ltd., Sanofi Pasteur and GlaxoSmithKline. Richard Roden is a founder of Papivax LLC. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. Reinhard Kirnbauer is a co-inventor on patent (7,361,356 Self-assembling recombinant papillomavirus capsid proteins), licensed to GlaxoSmithKline (GSK) and Merck (MSD). This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2014","05","Kihyuck Kwak","KK",6,TRUE,2,4,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
